Please login to the form below

Not currently logged in
Email:
Password:

pantoprazole

This page shows the latest pantoprazole news and features for those working in and with pharma, biotech and healthcare.

Pfizer settles US Protonix lawsuit for $785m

Pfizer settles US Protonix lawsuit for $785m

over-charged Medicaid for Protonix (pantoprazole), failing to offer the federal government the same discounts it was offering to private customers.

Latest news

  • Pfizer 2014 guidance threatened by Celebrex competition Pfizer 2014 guidance threatened by Celebrex competition

    The early onset of generic competition to Celebrex comes after a torrid time for Pfizer in terms of patent losses, with cholesterol lowerer Lipitor (atorvastatin), gastrointestinal medicine Protonix (pantoprazole), Viagra (sildenafil)

  • Teva defends Copaxone from Dutch patent challenge Teva defends Copaxone from Dutch patent challenge

    Maintaining Copaxone revenues is particularly important for Teva after it was ordered to pay $1.6bn in compensation to Pfizer and Takeda for infirming the patent on their Protonix (pantoprazole) gastrointestinal

  • Takeda expands Latin American footprint

    These will be ulcer treatments Zurcal (pantoprazole) and Riopan (Magaldrate Dimeticone), the anti-inflammatory Faktu (Policresulen, Cinchocaine hydrochloride) and Albothyl (Policresulen), a gynaecology product.

  • Pfizer sales dip as net income surges in Q2 Pfizer sales dip as net income surges in Q2

    from the spin-out of Zoetis and a litigation settlement with Teva and Sun Pharmaceutical Industries for patent infringement of Protonix (pantoprazole) fell 5 per cent.

  • Teva and Sun pay dearly for 'at-risk' generic Protonix launch

    The settlement marked the end of almost a decade of litigation over the intellectual property for Protonix (pantoprazole), and is the first time that generic pharma companies have been punished for ... Teva and Sun took a risk in 2007 and 2008 when they

More from news
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2013 Pharma deals during June 2013

    Top of the table is the patent settlement between Pfizer/ Takeda and Teva/ Sun Pharmaceutical for the launch of generic versions of Protonix (the proton pump inhibitor, pantoprazole) in 2007 ahead

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    For Nycomed this meant loss of exclusivity (LOE) on its blockbuster gastroinestinal drug pantoprazole and the consequent need to reorganise its business.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics